Q-omics provides the consensus-scored DIP2A-IT1 profile across patient tissues and cancer cell-line models. DIP2A-IT1 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, DIP2A-IT1 is differentially expressed in 7, with the highest sampling consensus in THCA. Additionally, DIP2A-IT1 RNA expression shows 8,496 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight READ, THCA, and LAML as cancer lineages where DIP2A-IT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DIP2A-IT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DIP2A-IT1 survival associations across molecular data types. DIP2A-IT1 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DIP2A-IT1 RNA expression–survival associations across cancer types. High DIP2A-IT1 expression shows unfavorable associations in LIHC and ACC, but favorable associations in READ, LUAD, UCS and PAAD. The READ Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify READ as the clearest survival context for DIP2A-IT1 RNA expression.
This table summarizes DIP2A-IT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for DIP2A-IT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DIP2A-IT1 shows lower tumor expression in THCA, STAD and BRCA and higher tumor expression in LIHC, UCEC and PRAD. The THCA box plot shows higher DIP2A-IT1 RNA expression in normal versus tumor tissue (log2 FC = −0.316, t-test p < 0.001).
This table shows molecular features associated with DIP2A-IT1 in patient tissues and cancer cell lines. In patient samples, DIP2A-IT1 shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set.
